17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α

294856-01-2

A number of 17-phenyl trinor prostaglandin F2α(17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma.1,2,3Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects.417-trifluoromethylphenyl-13,14-dihydro trinor PGF2αbears an aromatic ring which is reminiscent of the trifluoromethyl-phenoxy ring of travoprost ((+)-fluprostenol isopropyl ester).

C24H33F3O5

458.518

Powder: -20℃ for 3 years. In solvent: -80℃ for 1 year.

DMF: 30 mg/mLEthanol: 50 mg/mLPBS (pH 7.2): 1 mg/mLDMSO: 25 mg/mL